René Galien

981 total citations · 1 hit paper
32 papers, 706 citations indexed

About

René Galien is a scholar working on Oncology, Rheumatology and Genetics. According to data from OpenAlex, René Galien has authored 32 papers receiving a total of 706 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 12 papers in Rheumatology and 10 papers in Genetics. Recurrent topics in René Galien's work include Cytokine Signaling Pathways and Interactions (16 papers), Inflammatory Bowel Disease (9 papers) and Rheumatoid Arthritis Research and Therapies (8 papers). René Galien is often cited by papers focused on Cytokine Signaling Pathways and Interactions (16 papers), Inflammatory Bowel Disease (9 papers) and Rheumatoid Arthritis Research and Therapies (8 papers). René Galien collaborates with scholars based in Belgium, United States and Netherlands. René Galien's co-authors include Bernard P. Murray, Julie A. Di Paolo, Federico Campigotto, Amy Meng, Paqui G. Través, Gerben van ‘t Klooster, Annegret Van der Aa, Reginald Brys, Ellen M. van der Aar and L Nelles and has published in prestigious journals such as The Journal of Immunology, Gastroenterology and Journal of Medicinal Chemistry.

In The Last Decade

René Galien

30 papers receiving 692 citations

Hit Papers

JAK selectivity and the implications for clinical inhibit... 2021 2026 2022 2024 2021 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib
    2021 218 citations Paqui G. Través, Bernard P. Murray et al. Annals of the Rheumatic Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
René Galien Belgium 8 308 290 174 159 133 32 706
Florence Namour Belgium 14 194 0.6× 167 0.6× 150 0.9× 81 0.5× 99 0.7× 29 646
Matthew J. Saabye United States 8 190 0.6× 198 0.7× 85 0.5× 159 1.0× 116 0.9× 8 703
Julie A. Di Paolo United States 9 134 0.4× 148 0.5× 131 0.8× 168 1.1× 116 0.9× 17 521
Gabriele Stefanzl Austria 17 170 0.6× 151 0.5× 223 1.3× 279 1.8× 310 2.3× 38 794
Chris Planque France 15 197 0.6× 43 0.1× 181 1.0× 121 0.8× 76 0.6× 20 624
Carla B. Ripamonti Italy 14 89 0.3× 73 0.3× 146 0.8× 182 1.1× 354 2.7× 29 907
Maria Stella Pennisi Italy 14 187 0.6× 100 0.3× 235 1.4× 50 0.3× 283 2.1× 34 798
J Lyons Germany 8 123 0.4× 48 0.2× 201 1.2× 83 0.5× 424 3.2× 11 775
Cezary Swider United States 11 239 0.8× 79 0.3× 201 1.2× 175 1.1× 494 3.7× 20 1.1k
Elisa Funck‐Brentano France 14 377 1.2× 92 0.3× 33 0.2× 219 1.4× 25 0.2× 36 752

Countries citing papers authored by René Galien

Since Specialization
Citations

This map shows the geographic impact of René Galien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by René Galien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites René Galien more than expected).

Fields of papers citing papers by René Galien

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by René Galien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by René Galien. The network helps show where René Galien may publish in the future.

Co-authorship network of co-authors of René Galien

This figure shows the co-authorship network connecting the top 25 collaborators of René Galien. A scholar is included among the top collaborators of René Galien based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with René Galien. René Galien is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Galien, René, Maarten J. Deenen, Dirk Jan A. R. Moes, et al.. (2025). Precision Treatment of Patients With GI Cancer Using Pre-emptive DPYD Genotyping/Phenotyping Plus Pharmacokinetic-Guided Dosing of 5-Fluorouracil. JCO Precision Oncology. 9(9). e2500062–e2500062.
2.
Desroy, Nicolas, Nicolas Triballeau, Agnès Joncour, et al.. (2025). Design, Synthesis, and Biological Implications of Autotaxin inhibitors with a Three-Point lock binding mode. Bioorganic & Medicinal Chemistry. 124. 118181–118181. 2 indexed citations
3.
Blanqué, Roland, Kenji F. Shoji, Monica Borgonovi, et al.. (2024). Discovery of GLPG3667, a Selective ATP Competitive Tyrosine Kinase 2 Inhibitor for the Treatment of Autoimmune Diseases. Journal of Medicinal Chemistry. 67(11). 8545–8568. 5 indexed citations
4.
Blanqué, Roland, et al.. (2024). P133 In vitro pharmacological profile of GLPG3667 suggests differentiation from the TYK2 inhibitors deucravacitinib and TAK-279 at their clinical dose regimens. Journal of Crohn s and Colitis. 18(Supplement_1). i423–i423. 1 indexed citations
5.
Morand, Eric F., Roland Blanqué, Kenji F. Shoji, et al.. (2023). AB0144 PHARMACOLOGICAL CHARACTERIZATION OF GLPG3667, A SELECTIVE TYK2 INHIBITOR, SUPPORTS DEVELOPMENT IN DERMATOMYOSITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS. Annals of the Rheumatic Diseases. 82. 1251–1252. 1 indexed citations
6.
Reinisch, Walter, Adrian Serone, Xavier Hébuterne, et al.. (2022). Mucosal p-STAT1/3 correlates with histologic disease activity in Crohn’s disease and is responsive to filgotinib. Tissue Barriers. 11(2). 2088961–2088961. 3 indexed citations
7.
Través, Paqui G., Bernard P. Murray, Federico Campigotto, et al.. (2021). JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Annals of the Rheumatic Diseases. 80(7). 865–875. 218 indexed citations breakdown →
8.
Tarrant, Jacqueline M., René Galien, Wanying Li, et al.. (2020). Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials. Rheumatology and Therapy. 7(1). 173–190. 27 indexed citations
9.
Gladman, Dafna D., Andrew Hertz, Madhukar H. Trivedi, et al.. (2020). OP0224 FILGOTINIB TREATMENT LEADS TO RAPID AND SUSTAINED REDUCTIONS IN INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE TO SEVERE PSORIATIC ARTHRITIS. Annals of the Rheumatic Diseases. 79. 140–140. 1 indexed citations
10.
Roblin, Xavier, Adrian Serone, Ethan Grant, et al.. (2020). P535 Effects of the Janus Kinase 1 (JAK1)-selective inhibitor filgotinib on circulating cytokines and whole-blood genes/pathways of patients with moderately to severely active Crohn’s disease (CD). Journal of Crohn s and Colitis. 14(Supplement_1). S457–S458. 1 indexed citations
11.
Keshav, Satish, Xavier Roblin, Geert D’Haens, et al.. (2018). PTU-003 Filgotinib decreases inflammatory markers associated with endoscopic improvement in moderate to severely active crohn’s disease. A63.2–A64. 1 indexed citations
12.
Blanqué, Roland, et al.. (2017). FRI0428 The JAK1-selective inhibitor, filgotinib, inhibits inflammation pathways observed in an IL23-induced psoriatic arthritis mouse model. Annals of the Rheumatic Diseases. 76. 648–648. 1 indexed citations
13.
Vanhoutte, Frédéric, Minodora Mazur, Mykola Stanislavchuk, et al.. (2017). Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK‐1 Inhibitor, After Short‐Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials. Arthritis & Rheumatology. 69(10). 1949–1959. 61 indexed citations
14.
Namour, Florence, et al.. (2016). Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects. British Journal of Clinical Pharmacology. 82(1). 139–148. 47 indexed citations
15.
Galien, René. (2016). Janus kinases in inflammatory bowel disease: Four kinases for multiple purposes. Pharmacological Reports. 68(4). 789–796. 20 indexed citations
16.
Dupont, Sonia, Ingrid Arijs, Roland Blanqué, et al.. (2015). GPR84 inhibition as a novel therapeutic approach in IBD: mechanistic and translational studies. Ghent University Academic Bibliography (Ghent University). 1 indexed citations
17.
Namour, Florence, Béatrice Vayssière, René Galien, et al.. (2015). AB0494 Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, Shows Similar PK and PD Profiles in Japanese and Caucasian Healthy Volunteers. Annals of the Rheumatic Diseases. 74. 1063–1064. 6 indexed citations
18.
Namour, Florence, René Galien, Frédéric Vanhoutte, Piet Wigerinck, & Gerben van ‘t Klooster. (2013). THU0236 Once-Daily Dosing of GLPG0634, a Selective JAK1 Inhibitor, is Supported by Its Active Metabolite. Annals of the Rheumatic Diseases. 72. A244–A245. 1 indexed citations
19.
Rompaey, Luc Van, René Galien, Ellen M. van der Aar, et al.. (2013). Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases. The Journal of Immunology. 191(7). 3568–3577. 181 indexed citations
20.
Vayssière, Béatrice, Steve De Vos, Marielle Auberval, et al.. (2013). THU0116 Biological Effects of the JAK1 Selective Inhibitor GLPG0634 on Inflammation Markers in Arthritic Mice. Annals of the Rheumatic Diseases. 72. A201–A202.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Florence Namour Breakdown of academic impact, for papers by Matthew J. Saabye Breakdown of academic impact, for papers by Julie A. Di Paolo Breakdown of academic impact, for papers by Gabriele Stefanzl Breakdown of academic impact, for papers by Chris Planque Breakdown of academic impact, for papers by Carla B. Ripamonti Breakdown of academic impact, for papers by Maria Stella Pennisi Breakdown of academic impact, for papers by J Lyons Breakdown of academic impact, for papers by Cezary Swider Breakdown of academic impact, for papers by Elisa Funck‐Brentano
Rankless by CCL
2026